ImmunitoAI key facts
as of Oct 2026- Developer of an AI-powered platform for antibody discovery intended to accelerate the development of novel antibody therapeutics.
- ImmunitoAI is valued at approximately $21.4M as of Oct 2026 (last reported valuation).
- It has raised $9.1M; the latest was Later Stage VC ($6.1M) in Nov 2025.
- Notable investors include Google for Startups, Entrepreneurs First, LetsVenture Technologies, Anicut Capital, 3one4 Capital — 20 tracked in total.
- Status: Privately Held (backing).
ImmunitoAI's last reported valuation, Nov 2025. Nothing priced has surfaced since.
- ·The complete investor list: 20 names
- ·Watch ImmunitoAI: the Monday email on marks, rounds and moves
ImmunitoAI funding rounds
No funding rounds for ImmunitoAI are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs ImmunitoAI
20+ImmunitoAI valuation
ImmunitoAI's last reported valuation was $21.4 million in Nov 2025. No priced round, secondary trade or fund mark has surfaced since.
ImmunitoAI investors
20 investors are on record for ImmunitoAI, including Google for Startups, Entrepreneurs First, LetsVenture Technologies and Anicut Capital. By type, the record holds 4 venture capital firms and 1 family office.
About ImmunitoAI
Developer of an AI-powered platform for antibody discovery intended to accelerate the development of novel antibody therapeutics. The company's platform offers novel antibody and antibody fragments against any epitope and does not depend upon a biological source, animal or human, for the lead molecule, and antibody therapeutics with pre-defined drug properties, enabling healthcare institutions to save time and money and increase efficiency.
- Sector
- Healthcare
- HQ
- Bengaluru, India
- Founded
- 2020
- Employees
- 23
- Website
- immunitoai.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.